DLA
HRTX icon

Douglas Lane & Associates’s Heron Therapeutics HRTX Stock Holding History

Douglas Lane & Associates’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$17K – 249
2023
Q4 		$17K Hold
10,000
– – ﹤0.01% 243
2023
Q3 		$10.3K Hold
10,000
– – ﹤0.01% 233
2023
Q2 		$11.6K Hold
10,000
– – ﹤0.01% 234
2023
Q1 		$15.1K Hold
10,000
– – ﹤0.01% 226
2022
Q4 		$25K Buy
+10,000
New +$32.2K ﹤0.01% 225

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Douglas Lane & Associates's HRTX Position: Q1 2024 in Review

Douglas Lane & Associates sold out of Heron Therapeutics (HRTX) in Q1 2024, closing a stake of 10,000 shares — an estimated $17K sold.

Douglas Lane & Associates first reported a position in HRTX in Q4 2022 and held it in 5 quarters. The position peaked at $25K in Q4 2022. 161 funds tracked by Wall St. Rank hold HRTX as of Q1 2024.

  • Douglas Lane & Associates reported no remaining Heron Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Douglas Lane & Associates sold 10,000 Heron Therapeutics shares in Q1 2024, an estimated $17K.
  • Douglas Lane & Associates first reported a position in Heron Therapeutics in Q4 2022 and held it in 5 quarters.
  • Douglas Lane & Associates's Heron Therapeutics position peaked at $25K in Q4 2022.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2024.

Based on Douglas Lane & Associates's 13F filing for Q1 2024, filed 11 Apr 2024.